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OBJECTIVES: The objective of this analysis was to determine
the net economic beneﬁt to society from a SN60WF new tech-
nology intraocular lens (NTIOL) with an aspheric surface used
for the treatment of cataracts. METHODS: The incremental
costs of the aspheric SN60WF NTIOL were derived from the
additional $50 reimbursement paid by the U.S. Centers for
Medicare and Medicaid Services (CMS) for implantation of
NTIOLs in Medicare beneﬁciaries with cataracts. The economic
beneﬁts of the SN60WF were based on projected cost savings
from averted rear-end passenger vehicle collisions in the recipi-
ent population due to improved functional vision. Improved
functional vision was established using driving simulation results
comparing SN60WF recipients to patients implanted with a con-
ventional monofocal intraocular lens. A societal perspective and
a ten year time frame were used in the analysis. All costs and
beneﬁts were discounted at 3%. RESULTS: The incremental
costs to CMS for SN60WF implantation over the next decade
were estimated at $60 million U.S. dollars (USD). Driving sim-
ulation results indicated that SN60WF recipients performed
better than the control group in 34 of 36 driving tests. Further-
more SN60WF recipients were able to detect and identify poten-
tial road hazards from 0.5 to 1 second before the control patients
in 12 of the 36 tests. The economic beneﬁts from averted rear-
end passenger vehicle collisions were estimated in the range of
$105 to $158 million USD for the same 10 year period. Conse-
quently, the net economic beneﬁt to society was estimated
between $45 and $98 million USD over the next decade. A
threshold analysis revealed that a reduction in rear-end collisions
of 31% within the SA60WF recipient population was enough 
to offset the incremental NTIOL costs associated with the new
lens. CONCLUSION: Implantation of the NTIOL SN60WF in
cataract patients provides a net economic beneﬁt to society far
in excess of its incremental costs.
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OBJECTIVES: The objective of this study was to determine the
relative cost-effectiveness of three multifocal intraocular lenses
(IOLs) commonly implanted in cataract patients. METHODS: A
cost-effectiveness analysis was performed to determine the cost-
effectiveness ratios for the following three multifocal intraocular
lenses available in the U.S. health care market: an apodized dif-
fractive multifocal (ADM) IOL, a zonal refractive multifocal
(ZRM) IOL and an accommodating posterior chamber (APC)
IOL. The measure of effectiveness used was vision adjusted life
years (VALYs). VALYs are the product of the uncorrected near
visual acuity (UCNVA) provided by the IOLs and the average
life expectancy of the cataract patients. UCNVA, expressed in
decimal notation, and cost estimates were taken from the
medical literature. UCNVA was chosen as the measure of effect
because it is generally accepted that uncorrected distance visual
acuity outcomes are similar between the 3 alternative IOLs. The
economic perspective was that cataract patients enrolled in the
United States Medicare program. Only the direct incremental
costs of the multifocal IOLs were considered in the analysis. The
time span of the analysis was 14.2 years based on cataract
patients’ average life expectancy (ALE). No cost discounting was
performed because all incremental costs considered accrue in
year one. RESULTS: The average cost to patients for bilateral
multifocal IOL implantation was estimated at $4000. The
average UCNVAs, expressed in Snellen decimal notation, for the
ADM, ZRM and APC IOLs were 0.80, 0.57 and 0.7, respec-
tively. The VALY products of UCNVA and ALE for the ADM,
ZRM and APC IOLs were 11.36, 9.94 and 8.09 respectively. The
resultant VALY cost-effectiveness ratios for the ADM, ZRM and
APC IOLs were $352.11, $494.19 and $402.41, respectively.
CONCLUSION: Given the incremental cost associated with
multifocal IOLs the ADM IOL provides cataract patients with
the best value for their money.
PEY7
EFFECTIVENESS AND COSTS OF PROSTAGLANDINS,WITH
CAI OR AN ALPHA-2 AGONIST, IN THE TREATMENT OF
GLAUCOMA:ANALYSIS CONDUCTED ON THE UK GENERAL
PRACTITIONER RESEARCH DATABASE
Berdeaux G1, Lafuma A2, Guelfucci F2, Barnes R3
1Alcon France, Rueil-Malmaison, hauts de seine, France, 2Cemka-Eval,
Bourg-la-Reine, France, 3Alcon laboratories Inc, Fort Worth,TX, USA
OBJECTIVES: To compare the effectiveness and related costs of
prostaglandins (PG) associated with either alpha-2 agonists or
carbonic anhydrase inhibitors (CAI), in the treatment of glau-
coma, according to the UK General Practitioner Research Data-
base (UK-GPRD). METHODS: Data were extracted on patients
diagnosed with ocular hypertension or glaucoma who had
undergone topical treatment, surgery or laser therapy. A subse-
quent selection identiﬁed patients receiving prostaglandins asso-
ciated with an alpha-2 agonist (PG + alpha-2) or CA inhibitor
(PG + CAI). Treatment failure was deﬁned as a prescription
change (addition or removal of a topical treatment). Times to
treatment failure were compared using an adjusted Cox model.
Drugs, clinic visits and glaucoma procedures were collected over
a ﬁxed period for a cost minimization analysis, performed from
the NHS perspective. RESULTS: Data on 56,612 patients were
extracted and 39,808 had received at least one topical prescrip-
tion for glaucoma. The treatment for 1384 patients was PG +
alpha-2 and for 4792 patients PG + CAI. Patient characteristics
did not differ signiﬁcantly between the two populations. The
average age at diagnosis was 69.0 years and 47.6% were male.
Treatment failure within one year occurred for 70.0% of patients
receiving PG + alpha-2 and for 59.5% receiving PG + CAI (p <
0.001). The hazard ratio 0.822 for failure, after adjusting on age,
gender, and comorbidities, was less with PG + CAI (p < 0.001)
than PG + alpha-2. The adjusted cost of PG + alpha-2 treatment
(£441 p.a.) did not differ signiﬁcantly (p = 0.23) from PG + CAI
(£413). CONCLUSION: According to UK GPRD information,
PG + CAI is more efﬁcient than PG + alpha-2 for treating glau-
coma patients. Patients remained under treatment longer with
PG + CAI, than with PG + alpha 2, at a similar cost.
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OBJECTIVES: To compare the effectiveness and costs of beta-
blockers, combined with alpha-2 agonists or carbonic anhydrase
inhibitors (CAI), as replacements for failed ﬁrst-line treatments
in glaucoma, according to the UK General Practitioner Research
Database (UK-GPRD). METHODS: Data on treated ocular
hypertension or glaucoma patients (topical, surgical or laser
treatments) were extracted. Target patients were prescribed beta-
blockers with alpha-2 agonists or CA inhibitors as replacements
for failed treatment regimens. A subsequent change of prescrip-
tion (addition or removal of a topical treatment) constituted a
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treatment failure. Times to treatment failure, during a speciﬁed
observation period, were compared using an adjusted Cox
model. Drug consumption, clinic visits and glaucoma procedures
during the period were subjected to a cost minimization analy-
sis, adopting the NHS perspective. Results: Out of 56,612
patients elicited, 39,808 received at least one topical prescription
for glaucoma. Amongst these, 1164 were prescribed a β-
blocker+alpha-2 agonist and 5581 a β-blocker+CAI, in place of
failed treatments for glaucoma. No signiﬁcant demographic dif-
ferences were observed between groups. The mean age was 68.1
years and 51.9% were female. By the end of one year 69.7% of
patients failed to respond to β-blocker+alpha-2 as did 59.5% to
β-blocker+CAI (p < 0.001). The hazard ratio (0.818) for failure
was less for β-blocker+CAI (p < 0.001) than β-blocker+alpha-2,
after adjusting on age, gender, and comorbidities. Adjusted costs
of β-blocker+alpha-2 regimens were estimated at £357 p.a. and
were not statistically different (p = 0.61) from β-blocker+CAI
regimens (£348 p.a.). CONCLUSION: According to UK-GPRD
information, beta-blocker + CAI is more efﬁcient than beta-
blocker + alpha-2 in replacing failed treatments for glaucoma.
Patients continued longer with â blocker+CAI treatment than
beta-blocker + alpha-2, at a similar cost.
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OBJECTIVES: To compare the effectiveness and associated costs
of Travatan (prostaglandin) and Xalacom (prostaglandin + â-
blocker) as ﬁrst-line treatments for glaucoma, according to the
UK General Practitioner Research Database (UK-GPRD).
METHODS: Patients diagnosed with ocular hypertension or
glaucoma treated with a topical treatment, surgery or by laser
were identiﬁed. Patients conﬁrmed to have been prescribed ﬁrst
line Travatan or Xalacom monotherapy were selected. Treatment
failure was deﬁned as a prescription change (adding or remov-
ing a topical treatment). Time to treatment failure was compared
using an adjusted Cox model. Drugs, visits and glaucoma pro-
cedures consumed during a speciﬁed one-year period were
entered into a cost minimization analysis, viewed from a NHS
perspective. Results: 56,612 patients were identiﬁed and 39,808
had received at least one topical prescription for glaucoma; 176
received Xalacom and 639 got Travatan as ﬁrst-line treatments
for glaucoma. No signiﬁcant difference was found between the
characteristics of the two patient groups. Patients were 70.2
years old at diagnosis, on average, and 48.2% were male. At one
year, 35.8% of the patients failed with Xalacom, and 27.1%
failed with Travatan (p = 0.024). The hazard ratio for treatment
failure was 0.749 and less with Travatan (p = 0.04) than with
Xalacom, after adjusting for age, gender, and comorbidities.
Xalacom regimens were statistically (p < 0.001) more costly
(£328 p.a.) than Travatan regimens (£216 p.a.). CONCLU-
SION: According to UK-GPRD information, Travatan domi-
nated Xalacom as ﬁrst-line treatment for glaucoma patients.
Patients remained under Travatan treatment longer and at a
lower cost.
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OBJECTIVES: To determine the cost of blindness in the Czech
Republic. METHODS: Determination of cost is based on the
search of public database in 2006. Cost are calculated from the
state perspective, cost from the private sector are not included
(foundation, donation etc.). Analysis include direct cost: sup-
portive equipment, counseling, home care, co-morbidity treat-
ment, rehabilitation, retraining, social home for blind people,
social beneﬁts—allowance, community care and indirect cost:
productivity lost which was calculated via human capital
method. Three cost categories were selected to describe cost of
blindness: 1.) Blind in productive age, 2.) Blind in retirement
living at home, 3.) Blind in retirement placed in social home for
blind people. Costs in each group were divided in cost ﬁrst year
and following years. RESULTS: The cost is highest ﬁrst year in
group 1) blind in productive age and reach 733,000 CZK (app.
34,900 USD) per year. Following years is the cost lower 522,000
CZK (app. 24,900 USD) in this group. The second group which
includes blind people placed at home utilize 408,000 CZK (app.
19,400 USD) during ﬁrst year and 197,000 CZK following years
(9400 USD). The cost of third group which includes patients
living at social home was 324,000 CZK (15,400 USD) both ﬁrst
and following years. CONCLUSION: Cost of blindness from
ranges from 197,000 CZK to 733,000 CZK (app. 9400 to
34,900 USD) per year in the Czech Republic. Cost of blindness
represents a substantial burden for Czech state and society.
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OBJECTIVES: Develop a health economic model to measure the
standard of care costs associated with progression of primary
open angle glaucoma. METHODS: We used Monte Carlo tech-
niques to model the cost of a simulated cohort of 600 patients
with Mean Deviation (MD) score progression over four years.
MD scores were used to estimate resource utilization for the
cohort using regression equations from an analysis of the rela-
tionship between resources and MD score in the worst eye from
a U.S. chart review of glaucoma patients (N = 161, mean age
66.3, minimum follow-up of four years). Both medical (number
of ofﬁce visits, visual ﬁeld exams, trabeculoplasties and tra-
beculectomies) and pharmacy resources (number of glaucoma
medications) were included in the model. Unit costs were applied
to the resource utilization estimates. MD scores were also used
to predict utility scores based on a regression analysis of utility
scores among glaucoma patients; the quality-adjusted-life years
(QALYs) over four years was modeled. RESULTS: The four-year
cost for the cohort was $3957 per patient ($598 in pharmacy
costs and $3359 in medical costs) with 2.96 QALYs accumulated
over 4 years. CONCLUSION: Glaucoma progression as evi-
denced by worsening MD scores is associated with a loss in
quality of life and substantial costs over four years of follow-up.
Advances in understanding the economic burden of glaucoma
progression may help to guide strategies for preventing and
delaying onset of this disease and lead to cost savings by slowing
disease progression.
